alendronate has been researched along with naproxen in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Altman, RA; Borel, T; Davis, I; de Azambuja, F; Johnson, D; Liu, A; Sorrentino, JP; Udokwu, C; Yang, Y | 1 |
| Graham, DY; Malaty, HM | 1 |
| Gottlieb, S | 1 |
1 review(s) available for alendronate and naproxen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for alendronate and naproxen
| Article | Year |
|---|---|
Alendronate and naproxen are synergistic for development of gastric ulcers.
Topics: Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Drug Synergism; Duodenal Ulcer; Female; Gastric Mucosa; Gastroscopy; Humans; Male; Middle Aged; Naproxen; Single-Blind Method; Stomach Ulcer | 2001 |
Risk of ulcer soars with combination of arthritis drugs.
Topics: Administration, Oral; Adult; Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Interactions; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastroscopy; Humans; Naproxen; Prognosis; Risk Assessment; Stomach Ulcer | 2001 |
5 other study(ies) available for alendronate and naproxen
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
Topics: Bacterial Proteins; Binding Sites; Biosynthetic Pathways; Carboxy-Lyases; Catalytic Domain; Crystallography, X-Ray; Diflunisal; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kynurenine; Molecular Docking Simulation; NAD; Pseudomonas fluorescens; Structure-Activity Relationship; Tryptophan | 2021 |